Overcoming barriers to tumor genomic profiling through direct-to-patient outreach.
Seyram A Doe-TettehSabrina Y CampDalicia RealesJett CrowdisAnne Marie NoronhaBernadette WolffTina AlanoJesse GalleS Duygu SelcukluAgnes VialeNicholas D SocciYing L LiuWilliam P TewCarol AghajanianMarc LadanyiMeng Xiao HeSaud H AlDubayanRoei David MazorOfer ShpilbergOshrat Hershkovitz-RokahJose A RianchoJose Luis Hernández-HernándezM Carmen Gonzalez-VelaJustin J ButhornManda WilsonAmy E WebberMariko YabeKseniya Petrova-DrusMarc K RosenblumBenjamin H DurhamOmar Abdel-WahabMichael F BergerMark T A DonoghueAndrew L KungJulia L Glade BenderNeerav N ShuklaSamuel A FuntAhmet DoganRobert A SoslowHikmat A Al-AhmadieDarren R FeldmanEliezer Van AllenEli L DiamondDavid B SolitPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Direct-to-patient outreach can facilitate the assembly of cohorts of rare cancers of sufficient size to define their genomic landscape. By profiling tumors in a clinical laboratory, results could be reported to patients and their local physicians to guide treatment.